STAT

What we’ve learned about the coronavirus — and what we still need to know

As we approach the three-month mark of the spread of #coronavirus, the amount of information that’s been gained about it is staggering.
A man walks in a business district in Wuhan, where the coronavirus first emerged.

As we approach the three-month mark since we all learned about a new virus triggering serious respiratory infections in China, the amount of information that’s been gained about the new coronavirus is staggering.

In 2003, when SARS first emerged in China, it took weeks for laboratories to figure out what was causing new and sometimes deadly cases of pneumonia there and elsewhere.

This time, rumors of a possible new coronavirus were reported in China at the end of December, roughly the same time the country alerted the World Health Organization that it had a dangerous outbreak on its hands. By Jan. 10, the full genetic sequence of the virus had been shared with scientists around the globe.

The sharing of the sequence data has allowed countries around the world to ramp up testing for the virus, using laboratory-designed kits and scores of commercial tests now flooding the market. Those tests are critical to trying to lessen spread of the virus.

“The fact that so many tests are out there, the fact that there are so many testing platforms available now, is a remarkable success for science,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.

Related Books & Audiobooks